-
Beijing Balance Medical Receives Approval for Innovative Expandable Artificial Heart Valve in China
•
Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology company in China, has announced the approval of its limited expandable artificial biological heart valve by the Chinese regulatory authorities. This innovative valve is designed to replace diseased, injured, or malformed aortic, mitral, and tricuspid valves, as well…
-
WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership
•
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a memorandum of understanding (MOU) with South Korea-headquartered Boostimmune. This collaboration focuses on research and discovery services related to Boostimmune’s innovative pipelines. Under this agreement, WuXi Bio will serve as Boostimmune’s exclusive research and development service…
-
Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China
•
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with compatriot firm Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) concerning the drug Xpovio (selinexor). This agreement outlines the roles and responsibilities of both companies in the Chinese market. Responsibilities and Financial Terms of the AgreementAccording…
-
Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales
•
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the first half of 2023, with GLP-1 drugs and obesity sales propelling a 30% year-on-year (YOY) increase in revenues to DKK 107.7 billion (USD 15.9 billion) in constant exchange rates. Diabetes and Obesity Care Business ExpansionThe…
-
Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China
•
A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit claiming unfair dismissal following his raising of concerns about potential violations of the US Foreign Corrupt Practices Act (FCPA) within Pfizer’s China operations. Han, who served as Pfizer’s director of global compliance analytics, reported excessively…
-
Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars
•
US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023, highlighting a robust performance with revenues increasing by 4% year-on-year (YOY) in constant exchange rate terms to USD 1.6 billion. The Women’s Health and Biosimilars units emerged as the strongest growth drivers for the company.…
-
Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies
•
US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US firm Decibel Therapeutics Inc., (NASDAQ: DBTX), a partner since 2017 specializing in gene therapies for hearing loss. Regeneron is paying an initial USD 4 per Decibel share, valuing the transaction at approximately USD 109 million,…
-
Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919
•
US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial report that, in mutual agreement with development partner Takeda Pharmaceutical Co., Ltd (NYSE: TAK), the decision has been made to cease development of the Alzheimer’s drug candidate TAK-920/DNL919. This strategic decision was influenced by data…
